FDA orders vision loss warnings for GLP-1 weight-loss and diabetes drugs

The concern centres on nonarteritic anterior ischemic optic neuropathy, known as NAION. It is a rare eye condition that can cause significant vision loss, according to The Hindu.

Several medical studies have found an elevated risk of NAION among people taking GLP-1 medicines, MarketWatch reported. That evidence points to an association. The FDA's warning describes a potential increased risk, not a finding that the drugs definitively cause the condition.

On November 9, the FDA required GLP-1 manufacturers to inform patients and healthcare providers about the potential eye risk, STAT News reported. The action turns a safety concern into a requirement for drugmakers.

The required warning concerns an eye condition that can cause sudden blindness, according to NBC News. Reports identified widely used medicines including Ozempic and Wegovy as products that would carry the warning, Sky News reported on November 10.

More detail about the evidence emerged in November 10 coverage. An FDA analysis of 126 clinical trials involving 134,253 participants found higher NAION incidence among GLP-1 users than among people receiving placebos or other diabetes medicines, according to Mint.

The scope of the label changes also became clearer. Following an internal investigation, the FDA called for 12 GLP-1 medicines to add the rare eye risk to the warnings and precautions section of their labels, FiercePharma reported.

The FDA is requiring new warnings, with coverage identifying Ozempic, Wegovy, Zepbound and Mounjaro among the medicines involved, according to Ars Technica. The safety concern reaches drugs used for both weight management and diabetes, CNBC reported.

The distinction between severity and frequency matters here. The condition is rare, but its consequences can be permanent. The available coverage does not provide an absolute risk estimate, so it does not establish how many additional cases might occur among people taking these medicines.

The next concrete step is for manufacturers to update their product labels with the required warning, as reported by Euronews. The coverage provided does not specify a deadline for those changes or establish how the risk differs between individual medicines.